Industry / United Kingdom

Eisai Open European Knowledge Centre

June 2009 | Industry Trend Analysis

Despite the local pricing regulator recently turning down the expanded use of its key drug, Japanese pharmaceutical company

To read the full article, please take a trial.

Related Insight Articles

MHLW Approves Victoza And Equa

Industry / Japan Two patented drugs for the treatment of diabetes - Novo Nordisk's Victoza (liraglutide) and Novartis's Equa (vildagliptin) - have been registered in Japan. Despite the current popularity of emerging...

January 2010

OTC Sector Forecast Maintained

Industry / Japan BMI is maintaining its forecast for Japan's US$6bn over-the-counter (OTC) medicine market despite significant changes to the operating environment. Allowing the distribution of products in convenience...

June 2009

First Launch For Osteoporosis Drug

Industry / Japan Ono Pharmaceutical and Astellas Pharma have launched the new molecular entity (NME) Recalbon/Bonoteo (minodronic acid) in Japan for the treatment of osteoporosis. The development is significant because...

April 2009

A New 'Drug Lag' Record

Industry / Japan The cautious nature of Japan's regulatory regime has been demonstrated once again. A government panel has recommended approval of thalidomide for multiple myeloma ten years after it was registered in...

August 2008

Wockhardt To Distribute Sinclair Pharma's Medicines

Industry / United Kingdom In an effort to penetrate emerging markets, UK specialty drugmaker Sinclair Pharma has contracted Mumbai-based Wockhardt to distribute four of its products in India. The deal runs for 10 years and has...

June 2008